Immunotherapy and Immune Responses

This study shows that lung-targeted cytokine RNA-lipoplexes enhance anti-tumor immunity by activating T and NK cells and reducing Tregs, with efficacy in murine models and human lung tumor cultures.

This paper develops an IL6/1 fusokine that enhances T cell survival and anti-tumor response in a preclinical ovarian cancer model.

The paper identifies heterogeneous subpopulations within Type 1-polarized dendritic cells (DC1) and shows that IL-12p70 production is restricted to a rare subset, with implications for clinical variability.

This study develops a feeder-free method to generate functional human dendritic cells from pluripotent stem cells, outperforming monocyte-derived dendritic cells in antigen presentation and T cell activation.

This study evaluates clinically relevant vaccine adjuvants using a human immune organoid model, identifying AddaSO3 as consistently effective across early and prolonged immune response phases.

This study validates DoriVac, a DNA origami vaccine, as an effective treatment for metastatic melanoma in mouse models, showing reduced tumor nodules and enhanced immune activation when combined with PD-L1 blockade.

The paper introduces RADAR, a multi-omics pipeline to identify retired antigens as cancer vaccine targets, validating known targets and discovering novel candidates.

This paper develops an inhalable nanoparticle vaccine that co-delivers antigen and adjuvant to lysosomes, enhancing immune protection against bacterial pneumonia.

This paper evaluates poly(allylamine)/tripolyphosphate nanocomplex coacervates as a safe systemic adjuvant that activates the NLRP3 inflammasome to enhance Th1-dependent immune responses.

This study evaluates the ALTA(R) platform for vaccine formulation, showing enhanced humoral and cellular immune responses compared to liquid adjuvanted vaccines.

This paper identifies age-related impairment in systemic mRNA translation as a barrier to mRNA vaccine efficacy and develops an LNP formulation to restore transgene expression and T cell immunity in aged hosts.

The paper shows that overlapping MHC class I/II epitopes promote cDC1-like differentiation of moDC through mTORC1 inhibition, enhancing type 1 immunity.

The paper identifies that TNFα secretion by tumor-infiltrating myeloid DCs is critical for CD8 T cell cytotoxicity, and shows that DC vaccines lose this function, limiting their efficacy.

This study engineers bacterial outer membrane vesicles with cytokines to enhance antitumor efficacy in intratumoral immunotherapy, achieving tumor eradication in over 95% of mice.

This study shows that combining DAMP-inducing peptide nanofibers with a PAMP enhances lung-resident memory CD4+ T cell responses, improving protection against TB and respiratory diseases.

This study uses CRISPR screening to identify molecular targets that drive the function of tolerogenic dendritic cells, revealing CD86 and UBE2L6 as key regulators of immune tolerance.

This study shows that DOT1L influences dendritic cell subset development and antigen presentation by modulating histone H3K79 methylation.

This paper develops a nanoadjuvant that induces localized pyroptosis to generate vaccine-like pyroptosomes, enhancing anti-tumor immunity while avoiding systemic toxicity.

This paper identifies an MPO-derived epitope promiscuously presented by HLA-II molecules and develops a pan-allelic antibody that selectively targets AML cells while sparing normal myeloid cells.

This study shows that membrane-localized xenoantigens enhance CD4+ T cell responses and improve anti-PD-1 therapy efficacy in pre-immunized mice, using OVA and VZV gE antigens.

The paper identifies cross-presented tumor antigens in glioblastoma and shows that targeting these antigens with mRNA vaccines improves anti-tumor immunity.

This study shows that mutations in MR1 outside the antigen binding groove differentially affect exogenous antigen presentation by altering B2M association.

This paper identifies systemic reductions in dendritic cell (DC) numbers and activation markers in brain tumor patients, with brain tumors directly contributing to DC defects, and highlights corticosteroid use as a confounding factor.

This study shows B cells sustain Langerin+ cDC1s via LTβ and MMMs to support anti-viral CD8+ T cell responses during MCMV infection.

This paper shows tumor-derived extracellular vesicles induce ER stress in dendritic cells, promoting tolerogenic DCs that suppress antitumor immunity, and identifies PPAR-α inhibition as a potential therapeutic strategy.

This study shows that inducing oxidative stress in pancreatic cancer cells creates an effective whole-cell vaccine that enhances anti-tumor immunity and synergizes with PD-1 blockade.

The paper constructs an integrated atlas of tumor-infiltrating dendritic cells across species and immunotherapy conditions, revealing conserved activation states and spatial reorganization in response to therapy.

This study shows that RIPK1 deficiency or K376R mutation in dendritic cells enhances antitumor immunity by improving antigen presentation and T cell activation.

This paper re-engineers a cytolytic viral vector to be non-cytolytic, enhancing CD8 T cell immunity through reinforced type I IFN signaling.